Model Tiprelestat - Pioneering Anti-inflammatory and Tissue Protective Drug

• Tiprelestat is identical to the human protein elafin and a potent reversible inhibitor of human neutrophil elastase and proteinase 3. It’s able to inhibit their activity almost completely in vitro and in vivo.
• Tiprelestat is associated with a significantly reduced postoperative need for intensive care in patients undergoing esophageal cancer surgery.
• Tiprelestat inhibits the formation of neutrophil exosomes and neutrophil extracellular traps, inhibits NFkB and restores pathologic bone morphogenic protein signaling.
• Tiprelestat reduces, in vivo, vascular smooth muscle cell proliferation and vascular occlusion and promotes alveolar formation.
• Tiprelestat suppresses reperfusion injury occurring after heart transplantation, myocardial infarction, and skeletal muscle ischemia.
• Tiprelestat is able to revert the pathology in pulmonary arterial hypertension and to reduce ventilator induced injury.
• Tiprelestat is well tolerated and has been subjected to numerous preclinical and clinical investigations in a variety of disease areas.

HIGHLY INVASIVE SURGERY
Such as esophageal cancer surgery

PULMONARY INDICATIONS
Such as pulmonary arterial hypertension and COVID-19

CARDIOVASCULAR INDICATIONS
Such as coronary artery bypass graft surgery